Biotechnology

BIOSTAR PHARM-B

BIOSTAR PHARM-B released FY2025 9 Months Earnings on March 30 (BJT), with actual revenue of HKD 26.16 M and EPS of HKD -0.2761

BIOSTAR PHARM-B released FY2024 9 Months Earnings on March 30 (BJT), actual revenue HKD 57.22 M, actual EPS HKD -0.333

BIOSTAR PHARM-B released FY2024 Q3 earnings on March 30, 2026 (BJT), with actual revenue of HKD 21.47 M and EPS of HKD -0.1154

BIOSTAR PHARM-B released FY2025 Q3 earnings on March 30 (BJT), actual revenue HKD 10.15 M, actual EPS HKD -0.1157

BIOSTAR PHARM-B released FY2024 Q4 earnings on March 30 Pre-Market BJT, actual revenue HKD 20.61 M, actual EPS HKD -0.1108

BIOSTAR PHARM-B released FY2025 earnings on March 30 Pre-Market (BJT), actual revenue HKD 36.47 M (forecast HKD 220.18 M), actual EPS HKD -0.3934 (forecast HKD -0.4681)

BIOSTAR PHARM-B released FY2025 Q4 earnings on March 30 Pre-Market (BJT), actual revenue HKD 10.33 M, actual EPS HKD -0.1177

BIOSTAR PHARM-B to release FY2025 earnings on March 25, Pre-Market BJT, forecast revenue HKD 220.18 M, EPS HKD -0.4681

BIOSTAR PHARM-B released FY2024 Q2 earnings on August 28, 2025 (BJT) with actual revenue of HKD 17.8 M and EPS of HKD -0.1083

BIOSTAR PHARM-B released FY2024 Q1 earnings on August 28, 2025 (BJT) with actual revenue of HKD 17.95 M and EPS of HKD -0.1092

BIOSTAR PHARM-B released FY2025 Q1 earnings on August 28 (BJT), actual revenue HKD 7.918 M, actual EPS HKD -0.0793

BIOSTAR PHARM-B released FY2025 Q2 earnings on August 28 Pre-Market (BJT), actual revenue HKD 8.092 M, actual EPS HKD -0.0811

BIOSTAR PHARM-B released FY2025 Semi-Annual Earnings on August 28 Pre-Market (BJT), actual revenue HKD 16.01 M, actual EPS HKD -0.1604

BIOSTAR PHARM-B to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

BIOSTAR PHARM-B released FY2024 earnings on June 30 Pre-Market (BJT), actual revenue HKD 77.79 M (forecast HKD 91.49 M), actual EPS HKD -0.4438 (forecast HKD -0.567)

BIOSTAR PHARM-B to Release FY2024 Earnings on March 31, Pre-Market BJT; Forecast Revenue 91.92 M HKD, EPS -0.5696 HKD

BIOSTAR PHARM-B released FY2024 Semi-Annual earnings on October 22 (BJT), actual revenue HKD 35.74 M, actual EPS HKD -0.2175

SYNERTONE

TAILAM TECHCON

HAITIAN ANTENNA

SOFTMEDX

MICROWARE

WING FUNG GROUP

HIPINE

G-VISION INT'L

CHINA IN-TECH

02563

BIOSTAR PHARM-B announced that the results of four clinical studies of its core product Uteribulin will be presented at the 2026 ASCO Annual Meeting, covering areas such as breast cancer, ovarian cancer, and prostate cancer. The studies show that Uteribulin performs excellently across various indications, marking the company's transformation from Biotech to Biopharma. This presentation has gained recognition in the academic community, indicating the market potential and innovative value of its products

同壁财经

BHPCC

BIOSTAR PHARM-B intensively releases pipeline value signals: Four studies of Uteplizumab are set to debut at ASCO 2026, and innovative drugs in synthetic biology enter the global validation phase

BIOSTAR PHARM launched a 10% H-share repurchase plan and introduced Baiyang Pharmaceutical as a strategic investor, demonstrating the management's confidence in the current stock price. This move is seen as a signal of a bottom rebound and may open a valuation repair window. Baiyang Pharmaceutical subscribed to 25 million new shares at HKD 4 per share, indicating its recognition of BIOSTAR PHARM's intrinsic value

Baheal Medical

Bottom signal? BIOSTAR PHARM launched a 10% H-share repurchase plan, combined with Baiyang Pharmaceutical's stake acquisition, is the valuation repair window opening?

Beijing Biostar Pharmaceuticals Co., Ltd. has announced a plan to repurchase up to 10% of its H shares in the open market, pending regulatory and shareholder approvals. This buy-back aims to signal management's confidence in the company's outlook and enhance shareholder value. The company believes it can support this plan while maintaining a solid balance sheet, although repurchases will depend on market conditions and are at the board's discretion. The company's H shares are listed on the Hong Kong Stock Exchange, with a current market cap of HK$1.64B.

Tip Ranks

Beijing Biostar Pharmaceuticals Plans Discretionary H-Share Buy-Back to Signal Confidence

513700

BIOSTAR PHARM-B announced its 2025 annual performance, with revenue of RMB 33.36 million, a year-on-year decrease of 53.6%. Losses narrowed to RMB 131 million, compared to a loss of RMB 144 million in the same period last year; loss per share was RMB 0.36. No dividend was declared

AASTOCKS

Penghua CSI HK Connect Health Care Composite ETF

"Performance" BIOSTAR PHARM-B's annual loss narrowed to 131 million RMB, no dividend declared

588130

159837

560600

512290

159849

Huahao Zhongtian Pharmaceutical announced that the company has received a filing notice from the China Securities Regulatory Commission regarding its application issued on February 5, 2026. According to the filing notice, the company has completed the filing with the China Securities Regulatory Commission for the implementation of full circulation of H shares. The filing notice will be valid for 12 months from the date of issuance and will apply to the Stock Exchange for conversion and listing. However, the details of the conversion and listing implementation plan have not yet been finalized

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Huahao Zhongtian Pharmaceutical has completed the filing with the China Securities Regulatory Commission for the implementation of full circulation of H shares

02617

02610

09995

03868

01126

09678

02616

01788

00326

TRANSTHERA-B(02617) rose 16.87%, with a trading turnover 28.5 Million HKD, and a year-to-date rose 158.2%. NANSHAN AL INTL(02610) rose 16.26%, with a trading turnover 57.0 Million HKD, and a year-to-date rose 51.9%. REMEGEN(09995) rose 15.01%, with a trading turnover 1.6 Billion HKD, and a year-to-date rose 370.8%.

BIOSTAR PHARM-B(02563.HK)

BIOSTAR PHARM-B intensively releases pipeline value signals: Four studies of Uteplizumab are set to debut at ASCO 2026, and innovative drugs in synthetic biology enter the global validation phase

Bottom signal? BIOSTAR PHARM launched a 10% H-share repurchase plan, combined with Baiyang Pharmaceutical's stake acquisition, is the valuation repair window opening?

Beijing Biostar Pharmaceuticals Plans Discretionary H-Share Buy-Back to Signal Confidence

"Performance" BIOSTAR PHARM-B's annual loss narrowed to 131 million RMB, no dividend declared

Huahao Zhongtian Pharmaceutical has completed the filing with the China Securities Regulatory Commission for the implementation of full circulation of H shares

Top 10 HK Stock Gainers (7.4)